Biomarkers for Alzheimer's disease: A controversial topic

The Lancet Neurology

Volumn 14, Issue 8, 2015, Pages 781-783

  Frisoni, Giovanni B ^a,b   Visser, Pieter Jelle ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; MOLECULAR MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN METABOLISM; DEGENERATIVE DISEASE; DISEASE COURSE; HIPPOCAMPUS; HUMAN; MEDICAL RESEARCH; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC DISEASE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; AMYLOIDOSIS; BRAIN CORTEX; FEMALE; MALE; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; BIOLOGICAL MARKERS; CEREBRAL CORTEX; DISEASE PROGRESSION; FEMALE; HUMANS; MALE;

EID: 84937513463     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00150-7     Document Type: Note

References (10)

1. Le Couteur DG, Doust J, Creasey H, Brayne C Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis. BMJ 2013, 347:f5125.
2. Yau W-YW, Torascu DL, McDade EM, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol 2015, published online June 30. http://dx.doi.org/10.1016/S1474-4422(15)00135-0.
3. Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N), (accessed June 16, 2015). http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=265.
4. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015, 313:1939-1949.
5. Detsky AS What patients really want from health care. JAMA 2011, 306:2500-2501.
6. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015, 313:1924-1938.
7. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
8. Bertens D, Knol DL, Scheltens P, Visser PJ Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement 2015, 11:511-522.
9. Frisoni GB, Hampel H, O'Brien JT, Ritchie K, Winblad B Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. Lancet Neurol 2011, 10:598-601.
10. Herrup K The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 2015, 18:794-799.